Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Endologix, Inc. stock logo
ELGX
Endologix
$0.07
$0.03
$0.22
$7.10
$1.41M0.731.28 million shs85,372 shs
Endologix, Inc. stock logo
ELGXQ
Endologix
$0.02
$0.02
$0.01
$3.96
N/AN/AN/AN/A
Presbia PLC stock logo
LENSF
Presbia
$0.02
$0.02
$0.00
$0.19
$257K5.915,650 shsN/A
Medite Cancer Diagnostics, Inc. stock logo
MDIT
Medite Cancer Diagnostics
$0.00
$0.00
$0.01
N/AN/AN/AN/A
VRTT
Viatar CTC Solutions
$0.00
$0.00
$0.00
$0.02
$20K8.1825,633 shsN/A
Ten Starter Stocks For Beginners to Buy Now Cover

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Endologix, Inc. stock logo
ELGX
Endologix
0.00%0.00%0.00%0.00%0.00%
Endologix, Inc. stock logo
ELGXQ
Endologix
0.00%0.00%0.00%0.00%0.00%
Presbia PLC stock logo
LENSF
Presbia
0.00%0.00%0.00%0.00%0.00%
Medite Cancer Diagnostics, Inc. stock logo
MDIT
Medite Cancer Diagnostics
0.00%0.00%0.00%0.00%0.00%
VRTT
Viatar CTC Solutions
0.00%0.00%0.00%0.00%0.00%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Endologix, Inc. stock logo
ELGX
Endologix
N/AN/AN/AN/AN/AN/AN/AN/A
Endologix, Inc. stock logo
ELGXQ
Endologix
N/AN/AN/AN/AN/AN/AN/AN/A
Presbia PLC stock logo
LENSF
Presbia
N/AN/AN/AN/AN/AN/AN/AN/A
Medite Cancer Diagnostics, Inc. stock logo
MDIT
Medite Cancer Diagnostics
N/AN/AN/AN/AN/AN/AN/AN/A
VRTT
Viatar CTC Solutions
N/AN/AN/AN/AN/AN/AN/AN/A

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Endologix, Inc. stock logo
ELGX
Endologix
N/AN/AN/AN/A
Endologix, Inc. stock logo
ELGXQ
Endologix
N/AN/AN/AN/A
Presbia PLC stock logo
LENSF
Presbia
N/AN/AN/AN/A
Medite Cancer Diagnostics, Inc. stock logo
MDIT
Medite Cancer Diagnostics
N/AN/AN/AN/A
VRTT
Viatar CTC Solutions
N/AN/AN/AN/A

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Endologix, Inc. stock logo
ELGX
Endologix
$143.37M0.01N/AN/A$3.56 per share0.02
Endologix, Inc. stock logo
ELGXQ
Endologix
N/AN/AN/AN/AN/AN/A
Presbia PLC stock logo
LENSF
Presbia
N/AN/AN/AN/AN/AN/A
Medite Cancer Diagnostics, Inc. stock logo
MDIT
Medite Cancer Diagnostics
N/AN/AN/AN/AN/AN/A
VRTT
Viatar CTC Solutions
N/AN/AN/AN/AN/AN/A

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Endologix, Inc. stock logo
ELGX
Endologix
-$64.76M-$2.19N/AN/AN/A-44.65%-63.96%-13.26%N/A
Endologix, Inc. stock logo
ELGXQ
Endologix
N/AN/A0.00N/AN/AN/AN/AN/A
Presbia PLC stock logo
LENSF
Presbia
N/AN/A0.00N/AN/AN/AN/AN/A
Medite Cancer Diagnostics, Inc. stock logo
MDIT
Medite Cancer Diagnostics
N/AN/A0.00N/AN/AN/AN/AN/AN/A
VRTT
Viatar CTC Solutions
N/AN/A0.00N/AN/AN/AN/AN/A

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Endologix, Inc. stock logo
ELGX
Endologix
N/AN/AN/AN/AN/A
Endologix, Inc. stock logo
ELGXQ
Endologix
N/AN/AN/AN/AN/A
Presbia PLC stock logo
LENSF
Presbia
N/AN/AN/AN/AN/A
Medite Cancer Diagnostics, Inc. stock logo
MDIT
Medite Cancer Diagnostics
N/AN/AN/AN/AN/A
VRTT
Viatar CTC Solutions
N/AN/AN/AN/AN/A

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Endologix, Inc. stock logo
ELGX
Endologix
0.29
0.39
0.28
Endologix, Inc. stock logo
ELGXQ
Endologix
N/AN/AN/A
Presbia PLC stock logo
LENSF
Presbia
N/AN/AN/A
Medite Cancer Diagnostics, Inc. stock logo
MDIT
Medite Cancer Diagnostics
N/AN/AN/A
VRTT
Viatar CTC Solutions
N/AN/AN/A

Ownership

Institutional Ownership

CompanyInstitutional Ownership
Endologix, Inc. stock logo
ELGX
Endologix
51.61%
Endologix, Inc. stock logo
ELGXQ
Endologix
N/A
Presbia PLC stock logo
LENSF
Presbia
N/A
Medite Cancer Diagnostics, Inc. stock logo
MDIT
Medite Cancer Diagnostics
N/A
VRTT
Viatar CTC Solutions
N/A

Insider Ownership

CompanyInsider Ownership
Endologix, Inc. stock logo
ELGX
Endologix
1.30%
Endologix, Inc. stock logo
ELGXQ
Endologix
1.30%
Presbia PLC stock logo
LENSF
Presbia
74.20%
Medite Cancer Diagnostics, Inc. stock logo
MDIT
Medite Cancer Diagnostics
85.40%
VRTT
Viatar CTC Solutions
N/A

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
Endologix, Inc. stock logo
ELGX
Endologix
52819.17 millionN/AOptionable
Endologix, Inc. stock logo
ELGXQ
Endologix
488N/AN/ANot Optionable
Presbia PLC stock logo
LENSF
Presbia
2017.12 millionN/ANot Optionable
Medite Cancer Diagnostics, Inc. stock logo
MDIT
Medite Cancer Diagnostics
69N/AN/ANot Optionable
VRTT
Viatar CTC Solutions
819.72 millionN/ANot Optionable

ELGX, MDIT, LENSF, ELGXQ, and VRTT Headlines

SourceHeadline
Viatar CTC Solutions (OTC:VRTT), Earnings Estimates, EPS, and RevenueViatar CTC Solutions (OTC:VRTT), Earnings Estimates, EPS, and Revenue
benzinga.com - July 18 at 10:13 PM

Company Descriptions

Endologix logo

Endologix

NASDAQ:ELGX
Endologix, Inc. develops, manufactures, markets, and sells medical devices for the treatment of abdominal aortic aneurysms in the United States and internationally. The company offers minimally-invasive endovascular aneurysm repair (EVAR), including AFX (Anatomical Fixation) endovascular AAA system, which is a minimally invasive delivery system; VELA Proximal Endograft, which is designed for the treatment of proximal aortic neck anatomies with AFX; and the Ovation abdominal stent graft system. It also provides endovascular aneurysm sealing system (EVAS) product that is based on the Nellix EVAS system to seal the aneurysm, and provides blood flow to the legs through two blood lumens. In addition, the company offers proximal aortic extensions and limb extensions, which allow physicians to customize the implant to fit the patient's anatomy; and accessories to facilitate the delivery of its EVAR and EVAS products, including compatible guidewires, inflation devices, and snares. It sells its products through direct sales force, and a network of third party distributors and agents. The company was formerly known as Radiance Medical Systems, Inc. and changed its name to Endologix, Inc. in May 2002. Endologix, Inc. was founded in 1992 and is headquartered in Irvine, California.
Endologix logo

Endologix

OTCMKTS:ELGXQ
Endologix, Inc. develops, manufactures, markets, and sells medical devices for the treatment of abdominal aortic aneurysms in the United States and internationally. The company offers minimally-invasive endovascular aneurysm repair (EVAR), including AFX (Anatomical Fixation) endovascular AAA system, which is a minimally invasive delivery system; VELA Proximal Endograft, which is designed for the treatment of proximal aortic neck anatomies with AFX; and the Ovation abdominal stent graft system. It also provides endovascular aneurysm sealing system (EVAS) product that is based on the Nellix EVAS system to seal the aneurysm, and provides blood flow to the legs through two blood lumens. In addition, the company offers proximal aortic extensions and limb extensions, which allow physicians to customize the implant to fit the patient's anatomy; and accessories to facilitate the delivery of its EVAR and EVAS products, including compatible guidewires, inflation devices, and snares. It sells its products through direct sales force, and a network of third party distributors and agents. The company was formerly known as Radiance Medical Systems, Inc. and changed its name to Endologix, Inc. in May 2002. Endologix, Inc. was founded in 1992 and is headquartered in Irvine, California. On July 5, 2020, Endologix, Inc. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the Northern District of Texas. It is in joint administration with TriVascular Sales LLC.
Presbia logo

Presbia

OTCMKTS:LENSF
Presbia PLC, an ophthalmic device company, develops and markets optical lens implants for treating presbyopia. The company provides the refractive lens for patient surgeries, as well as accessories for procedures. It primarily operates in the United States, South Korea, Australia, Italy, the Netherlands, Ireland, Canada, and Germany. The company was founded in 2014 and is headquartered in Dublin, Ireland.
Medite Cancer Diagnostics logo

Medite Cancer Diagnostics

OTCMKTS:MDIT
Medite Cancer Diagnostics, Inc. operates as a medical technology company. It develops, manufactures, and markets molecular biomarkers, medical devices, and consumables for the detection, risk assessment, and diagnosis of cancerous and precancerous conditions and related diseases. The company offers USE 33, an ultrasonic decalcification instrument that automatically runs the process under controlled temperatures; TPC 15 Duo and Trio, a tissue processing instrument; TES 99 and TES Valida cooling units; and M530, A550, M380 microtomes for tissue sectioning. It also provides M630, a freezing microtome; TST44, a robotic multi-staining system; COT 20, a linear staining system; and RCM 9000, ACS 720, and TWISTER robotic coverslippers. In addition, the company develops SoftKit device for the self-collection of a sample that can be evaluated to provide an assessment of the health of the entire female genital tract. It sells its products through direct sales and distributors in the United States, China, Europe, and North Africa. The company serves histology and cytology laboratories associated with hospitals or research institutions, and independent laboratories. Medite Cancer Diagnostics, Inc. is based in Orlando, Florida.

Viatar CTC Solutions

OTCMKTS:VRTT
Viatar CTC Solutions Inc., a biotechnology company, focuses on developing and marketing cancer molecular diagnostics and cancer therapy products in the United States. Its products include Viatar collection system for molecular analysis that collects and purifies circulating tumor cells (CTCs) for DNA sequencing and other genetic analysis technologies used primarily for research; and Viatar therapeutic oncopheresis system to remove CTCs from a patient's blood as a new cancer therapy for metastatic disease. The company was formerly known as Vizio Medical Devices LLC and changed its name to Viatar CTC Solutions Inc. in February 2014. Viatar CTC Solutions Inc. was founded in 2007 and is headquartered in Lowell, Massachusetts.